American Cryostem Corp  

(Public, OTCMKTS:CRYO)   Watch this stock  
Find more results for LON:CRYO
+0.050 (25.00%)
Delayed:   12:25PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.25 - 0.29
52 week 0.10 - 0.51
Open 0.25
Vol / Avg. 12,100.00/12,220.00
Mkt cap 7.66M
P/E     -
Div/yield     -
EPS -0.04
Shares 36.77M
Beta -0.45
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -199.70% -407.03%
Operating margin -182.62% -340.69%
EBITD margin - -328.64%
Return on average assets -250.31% -256.95%
Return on average equity - -
Employees 6 -
CDP Score - -


1 Meridian Rd
EATONTOWN, NJ 07724-2242
United States - Map
+1-732-7471007 (Phone)
+1-732-7477782 (Fax)

Website links


American CryoStem Corporation is a developer and marketer of adipose tissue-based cellular technologies and related services. The Company focuses on clinical processing, commercial bio-banking and application development of cellular tools and applications using autologous adipose (fat) tissue and adipose derived stem cells (ADSCs). The Company's products and services include CELLECT, ATGRAFT, ATCELL, ACSELERATE, ACS Laboratories and International Licensing. The Company is in the business of collecting adipose tissue, processing it to separate the adult stem cells, and preparing such stem cells for long-term storage. Its ATGRAFT procedures include breast reconstruction, layered augmentation, buttocks enhancement or volume corrections of the hands, feet, face and neck areas. Its ACSelerate product is engaged in manufacturing various versions of its ACSelerate cell culture media, which include ACSelerate-MAX, ACSelerate-SFM, ACSelerate-CY, ACSelerate-MY, ACSelerate-CP and ACSelerate- TR.

Officers and directors

John S. Arnone Chairman of the Board and Chief Executive Officer
Age: 58
Anthony F. Dudzinski Chief Operating Officer and Director
Age: 53
John DiFolco Executive Vice President, Director - Marketing
Age: 31